Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 5, 2025CancersOpen Access

The Targeted Inhibition of Histone Lysine Demethylases as a Novel Promising Anti-Cancer Therapeutic Strategy—An Update on Recent Evidence

View Full Paper
Ask AI
Bookmark
Share

Authors

JPJarosław PaluszczakRKRobert Kleszcz

Discussion

Loading...

Member takes

Overview

Recent evidence highlights how KDM inhibitors may improve cancer treatment outcomes, suggesting novel strategies for therapy.

Key Points

  • Histone lysine demethylases have shown significant roles in cancer cell growth inhibition, both in vitro and in vivo.
  • Inhibition of KDMs impacts various cellular processes, including apoptosis, proliferation, and motility, revealing multifaceted anti-cancer effects.
  • KDM inhibitors can also enhance anti-cancer immune responses and improve sensitivity to radiation and chemotherapy.
  • This review discusses emerging evidence on the therapeutic potential of KDM inhibitors in cancer treatment.

Cite This Study

Paluszczak et al. (2025) studied this question.

synapsesocial.com/papers/68bb3a352b87ece8dc954e60https://doi.org/10.3390/cancers17172798
View Full Paper
Ask AI
Bookmark
Share